Pol, Stanislas Corouge, Marion Sogni, Philippe
Published in
Therapeutic advances in infectious disease
The treatment of hepatitis C virus (HCV) infection with pegylated interferon alpha and ribavirin leads to a sustained virologic response in around 50% of patients with HCV genotype 1, 65% with HCV genotype 4, 75% with HCV genotype 3 and around 80% with HCV genotype 2. A better understanding of the HCV lifecycle has resulted in the development of se...
Lawitz, Eric Sulkowski, Mark Jacobson, Ira Kraft, Walter K Maliakkal, Benedict Al-Ibrahim, Mohamed Gordon, Stuart C Kwo, Paul Rockstroh, Juergen Kurt Panorchan, Paul
...
Published in
Antiviral research
Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vaniprevir monotherapy in patients with genotype 1 chronic HCV infection. Treatment-naive and treatment-...
Hagan, Liesl M Wolpe, Paul Root Schinazi, Raymond F
Published in
Trends in microbiology
The availability of curative, direct-acting antiviral drugs against hepatitis C virus (HCV) sparks an ethical call for HCV eradication and provides essential tools to spearhead the effort. Challenges include increasing awareness of the chronic hepatitis C epidemic, garnering sufficient public, private, and governmental financial will to invest in t...
Gane, Edward J. Stedman, Catherine A. Hyland, Robert H. Ding, Xiao Svarovskaia, Evguenia Subramanian, G. Mani Symonds, William T. McHutchison, John G. Pang, Phillip S.
Published in
Gastroenterology
Background & AimsWe evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS-9669 in patients with genotype 1 hepatitis C virus (HCV) infection. MethodsA total of 113 patients were enrolled. Sofosbuvir (400 mg once daily) and LDV (9...
Pol, Stanislas Vallet-Pichard, Anaïs Corouge, Marion
Published in
Liver international : official journal of the International Association for the Study of the Liver
The treatment of hepatitis C virus (HCV) infection with pegylated interferon (PEG-IFN) alfa and ribavirin (800 mg daily) (RBV) is the standard of care (SOC) for hepatitis C virus genotype 3-infection leading to a sustained virological response (SVR) in around 65% of patients. A better understanding of the HCV life-cycle has recently resulted in the...
Conteduca, Vincenza Sansonno, Domenico Russi, Sabino Pavone, Fabio Dammacco, Franco
Published in
The Journal of infection
Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and social problem. The expanding knowledge of HCV lifecycle has led to the development of novel antiviral agents that: a) specifically target a viral function (direct-acting antivirals), or b) specifically inhibit viral replication. The present review describes the no...
Koh, Christopher Liang, T. Jake
Published in
Antiviral Research
With the introduction of direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection, the field is rapidly evolving towards interferon-free regimens with high sustained virologic response (SVR) rates. The ultimate goal of therapy in chronic HCV infection should include an easily dosed all-oral regimen that is highly effective, i...
Fofana, Isabel Jilg, Nikolaus Chung, Raymond T. Baumert, Thomas F.
Published in
Antiviral Research
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Furthermore, HCV-induced liver disease is the leading indication for liver transplantation. The recent introduction of direct-acting antivirals (DAAs) has revolutionized HCV treatment by making possible the cure of the majority of patients. However, their effi...
Zeuzem, Stefan DeMasi, Ralph Baldini, Alessandra Coate, Bruce Luo, Donghan Mrus, Joseph Witek, James
Published in
Journal of Hepatology
Background & AimsAnemia is a common adverse event associated with telaprevir-based triple therapy of chronic, genotype 1 hepatitis C. Identification of patients at risk of developing anemia could allow evaluation of suitability for therapy, and aid in determining frequency of anemia monitoring and treatment management. MethodsThis post-hoc analysis...
Deuffic-Burban, Sylvie Schwarzinger, Michaël Obach, Dorothée Mallet, Vincent Pol, Stanislas Pageaux, Georges-Philippe Canva, Valérie Deltenre, Pierre Roudot-Thoraval, Françoise Larrey, Dominique
...
Published in
Journal of Hepatology
Background & AimsIn treatment-naive patients mono-infected with genotype 1 chronic HCV, treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy are standard-of-care. However, more efficacious direct-acting antivirals (IFN-based new DAAs) are available and interferon-free (IFN-free) regimens are imminent (2015). MethodsA mathematical mo...